Hims & Hers stock traded more than 40% higher after the deal was announced.

Hims & Hers stock surged over 44% in premarket trading after a report said Novo Nordisk plans to sell its obesity drugs ...

March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy ...

The unexpected partnership comes one month after the Danish drugmaker decried Hims’ plan to sell a $49 copycat pill.

Add Yahoo as a preferred source to see more of our stories on Google. Advanced cancer detection, hormone therapies and microdoses of GLP-1 sound like medical treatments for the rich and chic. One ...

Novo Nordisk has sued Hims & Hers for patent infringement, saying the online site is selling cheaper, unapproved copies of the Wegovy weight loss drug ...

Hims & Hers is returning to the Super Bowl — one year after its debut spot kicked up a storm of controversy. The telehealth company announced Thursday that it will be returning to the Big Game with a ...

The ad, which aired during the Super Bowl over the weekend, promoted a new product by Hims & Hers, a blood test designed to detect over 50 types of cancer before symptoms appear. This includes hard-to ...

The telehealth platform expects its growth to continue this year, though its first-quarter guidance came in short of Wall ...

Hims & Hers Health Inc. HIMS shares are down during Tuesday’s premarket session as the company reported mixed fourth-quarter earnings results. The stock’s decline follows a report that revealed ...